Additional Positive Interim Results from Nanoform’s Clinical Study
Insider information Nanoform Finland Plc February 24, 2021 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Additional Positive Interim Results from Nanoform’s Clinical Study Helsinki, Finland – Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, today announced further positive interim results from its ongoing clinical study. The fast absorption data implies that small is powerful[®] and might offer viable alternatives to complex formulation approaches such as cyclodextrin based technologies. Nanoform has received the second interim